Stephen Shrewsbury, English Family Doctor
Stephen B. Shrewsbury is a physician whose 36+ year career has taken him from the intimate world of English family practice to the cutting edge of global drug development where physician scientists are creating therapeutics that will “patch” our disease-causing genes.
Stephen Shrewsbury, Pharmaceutical Industry physician
For 24 years he has worked for a series of pharmaceutical companies, starting with 9 years at GlaxoSmithKline, initially in the UK and then in the US, before moving to Chiron Corporation. Since 2002 he has lived and worked on the West Coast of North America.
Stephen Shrewsbury, Chief Medical Officer
After Chief Medical Officer roles with MAP Pharmaceuticals and Adamas Pharmaceuticals, he spent nearly three years as Chief Medical Officer of Sarepta Therapeutics (then called AVI BioPharma), a company focused on the development of drugs that will precisely and effectively correct some of the mistakes found in our genes. These innovative molecules, known as RNA-based therapeutic oligomers (or oligonucleotides), will finally offer physicians tools to address some of the most vexing medical conditions such as cancer, inherited diseases and lethal infections. In 2012, he became acting Chief Medical Officer to LifeSplice Pharma, another oligonucleotide company with a candidate drug for ALS and more in early development. He has invested in this company, underlining his enthusiasm for this exciting new breed of drug.
In 2013, he joined Aquinox Pharmaceuticals Inc in Vancouver, British Columbia, Canada, as Senior Vice President and Chief Medical Officer where he led their clinical programs with their lead SHIP1 activator drug, AQX-1125, in three important diseases: Bladder Pain Syndrome/ Interstitial Cystitis (BPS/IC), Chronic Obstructive Pulmonary Disease (COPD), and Atopic Dermatitis, taking their BPS/IC program from initial US clinical trial to it's pivotal, Phase 3 trial in 26 months. In March 2014, Dr. Shrewsbury helped Aquinox through its Initial Public Offering to become a publicly traded company on NASDAQ, with a further successful follow on public offering in September 2015. In June 2016, he moved to an early start up company working in Regenerative Medicine and in January 2017 he relaunched his Shrewd Consulting practice (www.shrewdconsulting.com)
Stephen Shrewsbury, Oligonucleotide Safety Working Group
From 2009 until ~ 2015, he served on the Oligonucleotide Safety Working Group (OSWG) – an international working group comprised of industry and regulatory authority members devoted to the safe development of oligonucleotides. He co-chaired a clinical session at the September 2013 FDA/DIA Oligonucleotide Therapeutic Conference which showcased the advances these new medicines had made in the previous 18 months.
Stephen Shrewsbury, Educator
Always passionate about educating others, in 2013 he established BioXpertz with a colleague. They launched an innovative, interactive and inexpensive web-based educational program for busy pharmaceutical and biotechnology employees.